Zoloft depletes which nutrients

Don't need the accessible version of this site? Hide the accessibility button Close modal window. Accessibility View Close toolbar. RSS Feed. Those on antidepressants are typically depleted of these important nutrients: Niacin Vitamin B3 - deficiency in this vitamin often contributes to neuropsychiatric and neurodegenerative disorders Folate- deficiency in this nutrient causes depressive symptoms Coenzyme Q defiency in this nutrient impairs mitochondrial function and increases oxidative stress Calcium- defiency in this nutrient can reduce bone mineral density Vitamin D- lack of this vitamin has been linked to depression Often times, because of these side effects, assessing the effectiveness of the antidepressant is difficult for doctors.

Sign-up using the form or call us at to take advantage of this exclusive offer. Location Find us on the map. Your use of this information means that you agree to the Terms of Use. Learn how we develop our content. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.

Drug Information Sertraline is a member of the selective serotonin reuptake inhibitor SSRI family of drugs used to treat people with depression. Common brand names: Zoloft. What Are Nutrient Interactions.

Types of interactions: Beneficial Adverse Check. Reduce Side Effects Ginkgo In three men and two women treated with fluoxetine or sertraline SSRI drugs closely related to paroxetine for depression who experienced sexual dysfunction, addition of Ginkgo biloba extract GBE in the amount of mg per day effectively reversed the sexual dysfunction. Support Medicine Chromium There have been five case reports of chromium supplementation — mcg per day significantly improving mood in people with a type of depression called dysthymic disorder who were also taking sertraline.

Reduces Effectiveness none. Explanation Required Grapefruit In a study of healthy volunteers, ingestion of grapefruit juice along with sertraline increased blood levels of the drug. Eating grapefruit or drinking grapefruit juice may therefore increase both the effectiveness and the adverse effects of sertraline. People taking sertraline should not consume grapefruit without medical supervision. The combination of SSRI and antidepressant medications with supplements can be especially dangerous.

If you have an anxiety disorder or depression , your doctor may prescribe a selective serotonin reuptake inhibitor SSRI. These are safe for most people, but when taken with supplements or vitamins, the results can be risky.

Brandi Cole, Pharm. Get the SingleCare prescription discount card. Heart J. Combined therapy with captopril and potassium supplementation. A potential for hyperkalemia. Brown R. Nitrendipine-induced gingival hyperplasia. First case report. Oral Surg. Oral Med.

Oral Pathol. Carty O. Case report: Drug-induced gingival overgrowth associated with the use of a calcium channel blocker amlodipine J.

Joshi S. Case Rep. Lawrence D. Calcium channel blocker-induced gingival hyperplasia: Case report and review of this iatrogenic disease. Madi M. West Indian Med. Livada R. Calcium channel blocker-induced gingival enlargement. Miller C. Incidence of verapamil-induced gingival hyperplasia in a dental population.

Sanz M. Current use of calcium channel blockers CCBs is associated with an increased risk of gingival hyperplasia. Anand V. An unusual toxicity with beta blocker and calcium channel blocker. Indian J. Care Med. Hoyt R. Hyperkalemia due to Salt Substitutes. Nishida Y. Comparative effect of angiotensin II type I receptor blockers and calcium channel blockers on laboratory parameters in hypertensive patients with type 2 diabetes. Watts G. Plasma coenzyme Q ubiquinone concentrations in patients treated with simvastatin.

Passi S. Mortensen S. Laaksonen R. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. High-dose statins and skeletal muscle metabolism in humans: A randomized, controlled trial. Asping M. Skarlovnik A. Caso G. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Fedacko J. Coenzyme Q 10 and selenium in statin-associated myopathy treatment.

Young J. Effect of coenzyme Q 10 supplementation on simvastatin-induced myalgia. Bookstaver D. Effect of coenzyme Q10 supplementation on statin-induced myalgias. Yavuz B. Increased levels of 25 hydroxyvitamin D and 1,dihydroxyvitamin D after rosuvastatin treatment: A novel pleiotropic effect of statins?

Drugs Ther. Ertugrul D. Anagnostis P. Open Cardiovasc. Reduced fracture risk in users of thiazide diuretics. Tissue Int. Ismail F. Effects of pravastatin and cholestyramine on circulating levels of parathyroid hormone and vitamin D metabolites. Montagnani M. Effects of pravastatin treatment on vitamin D metabolites. Ott C. Sathyapalan T. Atorvastatin increases hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Effect of atorvastatin on bone mineral density in patients with acute coronary syndrome.

Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Ahmed W. Glueck C. Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance.

Linde R. Kurnik D. Muscle pain and serum creatine kinase are not associated with low serum 25 OH vitamin D levels in patients receiving statins. Beulens J. Influence of duration and dose of metformin on cobalamin deficiency in type 2 diabetes patients using metformin.

Acta Diabetol. Iftikhar R. Pan Afr. Nervo M. Vitamin B12 in metformin-treated diabetic patients: A cross-sectional study in Brazil. Prevalence of vitamin B12 deficiency in type 2 diabetic patients using metformin: A cross-sectional study. Sao Paulo Med. Association of vitamin B12 deficiency and metformin use in patients with type 2 diabetes. Korean Med. De Groot-Kamphuis D.

Vitamin B12 deficiency and the lack of its consequences in type 2 diabetes patients using metformin. Ting R. Risk factors of vitamin B 12 deficiency in patients receiving metformin.

Pflipsen M. The prevalence of vitamin B 12 deficiency in patients with type 2 diabetes: A cross-sectional study. Board Fam. Liu Q. Zhang Q. Callaghan T. Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment. Bauman W. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin.

Diabetes Care. Habib Z. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. Solomon D. A cohort study of thiazolidinediones and fractures in older adults with diabetes. Schwartz A. Billington E. The effect of thiazolidinediones on bone mineral density and bone turnover: Systematic review and meta-analysis. Loke Y. Long-term use of thiazolidinediones and fractures in type 2 diabetes: A meta-analysis.

CMAJ Can. Briot K. Glucocorticoid-induced osteoporosis. RMD Open. Van Staa T. Hahn T. Effects off short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man.

Buckley L. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Adachi J. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: A 3 year followup. Bijlsma J. Effect of oral calcium and vitamin D on glucocorticoid-induced osteopenia.

Ringe J. Homik J. Calcium and vitamin D for corticosteroid-induced osteoporosis. Richy F. Inhaled corticosteroids effects on bone in asthmatic and COPD patients: A quantitative systematic review.

Jones A. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Bone mineral density and fracture risk with long-term use of inhaled corticosteroids in patients with asthma: Systematic review and meta-analysis.

BMJ Open. Weatherall M. Dose-response relationship for risk of non-vertebral fracture with inhaled corticosteroids. Risk of fractures with inhaled corticosteroids in COPD: Systematic review and meta-analysis of randomised controlled trials and observational studies.

Lewis S. Coppen A. Enhancement of the antidepressant action of fluoxetine by folic acid: A randomised, placebo controlled trial. Alpert M. Prediction of treatment response in geriatric depression from baseline folate level: Interaction with an SSRI or a tricyclic antidepressant.

Papakostas G. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: Predictors of clinical response in fluoxetine-resistant depression. The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. Ginsberg L.

Shelton R. Rizzoli R. Antidepressant medications and osteoporosis. Eom C. Use of selective serotonin reuptake inhibitors and risk of fracture: A systematic review and meta-analysis.

Panday K. Medication-induced osteoporosis: Screening and treatment strategies. Haney E. Wilson S. Oral contraceptive use: Impact on folate, vitamin B6, and vitamin B12; status. Wertalik L. Decreased serum B12 levels with oral contraceptive use.

Serum folate and Vitamin B12 levels in women using modern oral contraceptives OC containing 20 microg ethinyl estradiol. Veninga K. Effects of oral contraceptives on vitamins B6, B12, C, and folacin. Berenson A. Effect of hormonal contraceptives on vitamin B12 level and the association of the latter with bone mineral density.

McArthur J. Biological variability and impact of oral contraceptives on vitamins B 6 , B 12 and folate status in women of reproductive age. Riedel B. Effects of oral contraceptives and hormone replacement therapy on markers of cobalamin status. Shojania A. The effect of oral contraceptives on vitamin B12 metabolism. Plasma homocysteine in women on oral oestrogen-containing contraceptives and in men with oestrogen-treated prostatic carcinoma.

Streiff R. Folate Deficiency and Oral Contraceptives. Oral contraceptives and serum-folate level. Shere M. Gambacciani M. Longitudinal evaluation of perimenopausal bone loss: Effects of different low dose oral contraceptive preparations on bone mineral density. Kleerekoper M. Oral contraceptive use may protect against low bone mass. Kuohung W. Low-dose oral contraceptives and bone mineral density: An evidence-based analysis.

Liu S. Effect of oral contraceptives and hormone replacement therapy on bone mineral density in premenopausal and perimenopausal women: A systematic review. Sports Med. Hartard M. Age at first oral contraceptive use as a major determinant of vertebral bone mass in female endurance athletes. Cobb K. Coronary Risk Development in Young Adults. Effects on bone mineral density of low-dosed oral contraceptives compared to and combined with physical activity. Burr D. Exercise and oral contraceptive use suppress the normal age-related increase in bone mass and strength of the femoral neck in women years of age.

Weaver C. Impact of exercise on bone health and contraindication of oral contraceptive use in young women. Sports Exerc. Teegarden D. Dietary calcium intake protects women consuming oral contraceptives from spine and hip bone loss. Hameed A. Effect of oral and injectable contraceptives on serum calcium, magnesium and phosphorus in women.

Ayub Med. Olatunbosun D. Effect of oral contraceptives on Serum magnesium levels. Akinloye O. Effects of contraceptives on serum trace elements, calcium and phosphorus levels. Stanton M. Serum magnesium in women during pregnancy, while taking contraceptives, and after menopause. Blum M. Oral contraceptive lowers serum magnesium.

Effect of oral contraceptive agents on nutrients: I. Stegeman B. Different combined oral contraceptives and the risk of venous thrombosis: Systematic review and network meta-analysis. Termanini B. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Den Elzen W. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Ito T. Pennypacker L.

High prevalence of cobalamin deficiency in elderly outpatients. Furuta T. Drug Metab. Kittang E. Effect of omeprazole on the secretion of intrinsic factor, gastric acid and pepsin in man. Freedberg D. Tempel M. Stewart C. Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy.

Sarzynski E. Association between proton pump inhibitor use and anemia: A retrospective cohort study. Lam J. Hutchinson C. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Sipponen P. Hypochlorhydric stomach: A risk condition for calcium malabsorption and osteoporosis? McGowan B. Prescribing of anti-osteoporotic therapies following the use of proton pump inhibitors in general practice.

Drug Saf. Ngamruengphong S. Proton pump inhibitors and risk of fracture: A systematic review and meta-analysis of observational studies. Zhou B. Proton-pump inhibitors and risk of fractures: An update meta-analysis. Graziani G. Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects.

Serfaty-Lacrosniere C. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans.

Gray S. Acid-suppressive medications and risk of bone loss and fracture in older adults. Targownik L. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Cosman F. Sheen E. Adverse effects of long-term proton pump inhibitor therapy. Sturniolo G. Inhibition of gastric acid secretion reduces zinc absorption in man. Ozutemiz A. Effect of omeprazole on plasma zinc levels after oral zinc administration.

Farrell C. Tang G. Gastric acidity influences the blood response to a beta-carotene dose in humans.